Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Antioxidants Could Actually Promote Cancer Progression

By BiotechDaily International staff writers
Posted on 21 Jan 2013
Image: Prof. James D. Watson, PhD (Photo courtesy of Jan Arkesteijn).
Image: Prof. James D. Watson, PhD (Photo courtesy of Jan Arkesteijn).
Nobel laureate Prof. James Watson, PhD, has launched a scathing critique on antioxidant supplements, claiming they may have caused more cancers than they have prevented.

In a paper titled “Oxidants, antioxidants and the current incurability of metastatic cancers” Professor Watson, one of the discoverers of the DNA double-helix and former director and president of Cold Spring Harbor Laboratory (New York, NY, USA) points out that the vast majority of all agents used to directly kill cancer cells, including ionizing radiation, most chemotherapeutic agents, and some targeted therapies, work either directly or indirectly by generating reactive oxygen species (ROS) that block key steps in the cell cycle, allowing dysfunctional cells which pose a threat to the survival or organisms to kill themselves.

ROS, however, are also able to irreversibly damage key proteins and nucleic acid molecules (such as DNA and RNA) in normal cells. Thus, under circumstances in which they are actually not needed to curb dysfunctional cells, ROS are constantly being neutralized by antioxidative proteins. In order to aid this neutralization, we are often urged to eat foods rich in antioxidants, such as blueberries or carrots. Prof. Watson claims that in late-stage cancer, as ROS are needed for apoptosis, suppressing them may promote the progression of threatening cells and hence cancer.

Prof. Watson also claims that this action of antioxidant supplements could also explain why cancers that develop resistance to chemotherapeutic control become equally resistant to ionizing radiotherapy, since the common feature would be their common dependence upon a ROS-mediated cell-killing mechanism. Watson also applies his theory to suggest that cancer cells largely driven by mutant proteins such as the RAS and MYC oncogenes are often hardest to respond to treatments, due to their high levels of ROS-destroying antioxidants. The thesis was published on January 8, 2012, in Open Biology.

“For as long as I have been focused on the understanding and curing cancer, well-intentioned individuals have been consuming antioxidative nutritional supplements as cancer preventatives if not actual therapies,” concluded Prof. Watson. “In light of the recent data strongly hinting that much of late-stage cancer's untreatability may arise from its possession of too many antioxidants, the time has come to seriously ask whether antioxidant use much more likely causes, than prevents, cancer; ‘had best be eaten because they taste good, not because their consumption will lead to less cancer’.”

Recent studies have shown that antioxidant supplements have negligible positive effect on healthy people, at least in terms of important things such as preventing cancer or premature death. Some supplements--notably vitamins A, E, and beta-carotene—even seem to slightly raise the risk of disease and early death.

Related Links:
Cold Spring Harbor Laboratory


Channels

Genomics/Proteomics

view channel
Image: The bone marrow of mice with normal ether lipid production (top) contains more white blood cells than are found in the bone marrow of mice with ether lipid deficiency (bottom) (Photo courtesy of Washington University School of Medicine).

Inactivating Fatty Acid Synthase Reduces Inflammation by Interfering with Neutrophil Membrane Function

The enzyme fatty acid synthase (FAS) was shown to regulate inflammation by sustaining neutrophil viability through modulation of membrane phospholipid composition. Neutrophils are the most abundant... Read more

Drug Discovery

view channel
Image: Researchers have attached two drugs—TRAIL and Dox—onto graphene strips. TRAIL is most effective when delivered to the external membrane of a cancer cell, while Dox is most effective when delivered to the nucleus, so the researchers designed the system to deliver the drugs sequentially, with each drug hitting a cancer cell where it will do the most damage (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Anticancer Drug Delivery System Utilizes Graphene Strip Transporters

The ongoing search by cancer researchers for targeted drug delivery systems has generated a novel approach that uses graphene strips to transport simultaneously the anticancer agents TRAIL (tumor necrosis... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Biotech Acquisition Designed to Accelerate the Development and Marketing of Immunosequencing Applications

Adaptive Biotechnologies Corp. (Seattle, WA, USA), a developer of next-generation sequencing (NGS) to profile T-cell and B-cell receptors, has acquired of Sequenta, Inc. (South San Francisco, CA, USA), which is expected to expedite and expand the use of innovative immunosequencing technology for researchers and clinicians... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.